The gene-editing technology known as CRISPR has attracted much excitement and investor interest with its potential to someday treat diseases by fixing faulty copies of genes. But recently, a different approach called RNA editing, which could offer advantages over CRISPR, has been gaining ground in academic labs and start-ups, according to an article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society.
RNA editing uses an enzyme called ADAR to make precise edits to RNA, the shorter-lived cousin to DNA that acts as a blueprint for proteins. Researchers direct ADAR to specific RNAs with a guide sequence attached to the enzyme. Unlike CRISPR gene editing, the effects of RNA editing are reversible because cells are constantly making new copies of RNA. Therefore, RNA editing avoids the risks of permanent gene editing with CRISPR, writes Assistant Editor Ryan Cross, and could also be used to treat temporary conditions, such as pain or inflammation.
However, finding an easy way to control how ADAR makes its edits has been challenging. Researchers have tried chemically attaching ADAR to a guide RNA, adding an RNA-binding protein or even linking the catalytic portion of ADAR to the bacterial Cas9 enzyme used in CRISPR. However, these approaches require getting the modified enzymes into human cells. Some researchers are working on using human cells’ own ADAR for RNA editing, by introducing chemically modified guide RNAs that recruit the editing enzyme and direct it to specific RNAs. With researchers and investors becoming increasingly interested in this approach, RNA editing could someday give CRISPR a run for its money, Cross writes.
The article, “Watch out, CRISPR. The RNA editing race is on,” is freely available here.
Learn more: Interest in RNA editing heats up
The Latest on: RNA editing
[google_news title=”” keyword=”RNA editing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: RNA editing
- Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systemson May 1, 2024 at 1:00 pm
Enhances strategic flexibility and control of key gene editing technologies and programsEMERYVILLE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MGX), a precision genetic medicines company ...
- Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlighton May 1, 2024 at 1:00 pm
Earlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting stage left on a partnership worth up to $3 billion in biobucks.
- Vesigen to Present New Preclinical Data on Ophthalmology Applications of Engineered ARMMs at 2024 ARVO Annual Meetingon May 1, 2024 at 8:03 am
non-viral delivery technology for gene editing, RNA, and protein-based therapeutics. Vesigen’s patented technology, ARMMs (ARRDC1 Mediated Microvesicles), can precisely deliver a wide range of ...
- Shape Therapeutics to Showcase RNA Editing in the Brain and Validation of their Stable AAV ...on April 30, 2024 at 5:01 am
Shape Therapeutics, a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, today announced its upcoming oral presentations at ...
- Shape Therapeutics to Showcase RNA Editing in the Brain and Validation of their Stable AAV Producer Cell Line at ASGCT 2024on April 30, 2024 at 5:00 am
Shape Therapeutics, a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, today announced its upcoming oral presentations at the 27th American Society for Gene and Cell ...
- Gene seekers discover atypical genes that control multiple valuable soybean traitson April 30, 2024 at 1:27 am
A team led by Purdue University soybean geneticist Jianxin Ma has developed a new biotechnological tool for the domestication of desirable traits from wild soybeans, such as resistance to leafhopper ...
- Scientists' research on RNA editing illuminates possible lifesaving treatments for genetic diseaseson April 29, 2024 at 7:09 am
A team at Montana State University published research this month that shows how RNA, the close chemical cousin to DNA, can be edited using CRISPRs. The work reveals a new process in human cells that ...
- ‘ChatGPT for CRISPR’ creates new gene-editing toolson April 28, 2024 at 5:00 pm
This week, researchers published details of how they used a generative AI tool called a protein language model — a neural network trained on millions of protein sequences — to design CRISPR ...
- Wave Life Sciences announced continued momentum in GSK Collaboration and Advancements in siRNA and RNA Editingon April 27, 2024 at 6:27 am
Dr. Paul Bolno, President and CEO of Wave Life Sciences, remarks, "We've reached an exciting juncture in our collaborative research with GSK, with the selection of the first two programs marking a ...
- ProQR defends RNA editing platform at EPOon April 23, 2024 at 8:31 am
Dutch biotech ProQR has successfully defended a patent covering its ribonucleic acid (RNA) editing platform Axiomer, following an opposition at the European Patent Office (EPO) filed in June 2021. On ...
via Bing News